374 related articles for article (PubMed ID: 21571868)
21. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.
Osipo C; Meeke K; Cheng D; Weichel A; Bertucci A; Liu H; Jordan VC
Int J Oncol; 2007 Feb; 30(2):509-20. PubMed ID: 17203234
[TBL] [Abstract][Full Text] [Related]
22. Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention.
Sabnis G; Brodie A
Clin Breast Cancer; 2010 Feb; 10(1):E6-E15. PubMed ID: 20133251
[TBL] [Abstract][Full Text] [Related]
23. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
24. Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer.
Sims AH; Zweemer AJ; Nagumo Y; Faratian D; Muir M; Dodds M; Um I; Kay C; Hasmann M; Harrison DJ; Langdon SP
Br J Cancer; 2012 May; 106(11):1779-89. PubMed ID: 22549178
[TBL] [Abstract][Full Text] [Related]
25. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
[TBL] [Abstract][Full Text] [Related]
26. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression.
Menderes G; Bonazzoli E; Bellone S; Altwerger G; Black JD; Dugan K; Pettinella F; Masserdotti A; Riccio F; Bianchi A; Zammataro L; de Haydu C; Buza N; Hui P; Wong S; Huang GS; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2017 Oct; 147(1):145-152. PubMed ID: 28705408
[TBL] [Abstract][Full Text] [Related]
27. Multiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers.
Ciucci A; Zannoni GF; Buttarelli M; Lisi L; Travaglia D; Martinelli E; Scambia G; Gallo D
Oncotarget; 2016 Feb; 7(7):8155-71. PubMed ID: 26797759
[TBL] [Abstract][Full Text] [Related]
28. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM
J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342
[TBL] [Abstract][Full Text] [Related]
29. Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.
Jain R; Rawat A; Verma B; Markiewski MM; Weidanz JA
J Natl Cancer Inst; 2013 Feb; 105(3):202-18. PubMed ID: 23300219
[TBL] [Abstract][Full Text] [Related]
30. Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.
Collins D; Jacob W; Cejalvo JM; Ceppi M; James I; Hasmann M; Crown J; Cervantes A; Weisser M; Bossenmaier B
PLoS One; 2017; 12(5):e0177331. PubMed ID: 28493933
[TBL] [Abstract][Full Text] [Related]
31. A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells.
Khalil HS; Langdon SP; Goltsov A; Soininen T; Harrison DJ; Bown J; Deeni YY
Oncotarget; 2016 Nov; 7(46):75874-75901. PubMed ID: 27713148
[TBL] [Abstract][Full Text] [Related]
32. Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance.
Pedersen MW; Jacobsen HJ; Koefoed K; Dahlman A; Kjær I; Poulsen TT; Meijer PJ; Nielsen LS; Horak ID; Lantto J; Kragh M
Mol Cancer Ther; 2015 Mar; 14(3):669-80. PubMed ID: 25612619
[TBL] [Abstract][Full Text] [Related]
33. Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice.
Hirakawa H; Yokoyama Y; Yoshida H; Mizunuma H
J Ovarian Res; 2014 Jan; 7():4. PubMed ID: 24410765
[TBL] [Abstract][Full Text] [Related]
34. Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy.
Itamochi H; Kigawa J; Kanamori Y; Oishi T; Bartholomeusz C; Nahta R; Esteva FJ; Sneige N; Terakawa N; Ueno NT
Mol Cancer Ther; 2007 Jan; 6(1):227-35. PubMed ID: 17218636
[TBL] [Abstract][Full Text] [Related]
35. miRNA-150 downregulation promotes pertuzumab resistance in ovarian cancer cells via AKT activation.
Wuerkenbieke D; Wang J; Li Y; Ma C
Arch Gynecol Obstet; 2015 Nov; 292(5):1109-16. PubMed ID: 25986891
[TBL] [Abstract][Full Text] [Related]
36. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
O'Regan RM; Osipo C; Ariazi E; Lee ES; Meeke K; Morris C; Bertucci A; Sarker MA; Grigg R; Jordan VC
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2255-63. PubMed ID: 16609042
[TBL] [Abstract][Full Text] [Related]
37. Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.
Ricci F; Fratelli M; Guffanti F; Porcu L; Spriano F; Dell'Anna T; Fruscio R; Damia G
Oncotarget; 2017 Jan; 8(5):7441-7451. PubMed ID: 26910918
[TBL] [Abstract][Full Text] [Related]
38. Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3.
Wang W; Zhang Y; Lv M; Feng J; Peng H; Geng J; Lin Z; Zhou T; Li X; Shen B; Ma Y; Qiao C
J Ovarian Res; 2014 Nov; 7():103. PubMed ID: 25424625
[TBL] [Abstract][Full Text] [Related]
39. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.
Baselga J; Swain SM
Clin Breast Cancer; 2010 Dec; 10(6):489-91. PubMed ID: 21147694
[TBL] [Abstract][Full Text] [Related]
40. Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer.
Shao M; Hollar S; Chambliss D; Schmitt J; Emerson R; Chelladurai B; Perkins S; Ivan M; Matei D
Mol Cancer Ther; 2012 Jul; 11(7):1576-86. PubMed ID: 22700681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
